‘Digoxin conundrum – Time for validation?’

Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent Europea...

Descripción completa

Detalles Bibliográficos
Autor principal: Yadava, O.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065360/
https://www.ncbi.nlm.nih.gov/pubmed/33865529
http://dx.doi.org/10.1016/j.ihj.2021.01.019
Descripción
Sumario:Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.

Ejemplares similares